This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > RBX-2660 for the Treatment of Recurrent Clostridium Difficile Infection – third line

< Back

RBX-2660 for the Treatment of Recurrent Clostridium Difficile Infection – third line


Infectious Disease and Immunisation

January 2018

Clostridium difficile (C. difficile) is a type of bacterium that lives in people’s guts. When this bacterium grows in number, it can cause an infection, C. difficile infection (CDI) that can be mild, moderate or severe. Occasionally, after initial treatment with antibiotics, the infection can re-occur, and the more times the infection re-occurs, the more likely is this to happen again. When infection happens for second and subsequent times, treatment options become more limited and less effective. Symptoms of CDI include watery diarrhoea, painful stomach cramps, dehydration, loss of appetite, weight loss.
RBX-2660 is a therapy under development for recurrent CDI. It is a non-antibiotic therapy that consists of human-derived microorganisms (microbiota suspension). It is administered directly into the patient’s intestine through the rectum as an enema. RBX-2660 has the potential to treat patients re-infected by C. difficile that currently have limited treatment options available and are at risk of serious health consequences.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts